SCI & TECH● LOWSep 8 · Sep 8, 2026, 1:27 PM
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial
Seeking Alpha Tech · global
A cancer therapy developed by Inhibrx has reportedly shown superior performance to Merck's Keytruda in a mid-stage clinical trial. This indicates a potential advancement in cancer treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH26m agoAfter a decade of disruption, Pattanam needs a renewed visionThe HinduSCI & TECH1h agoISS mission: 'It's really exciting to see this renewal of French women in space'France 24 [en]SCI & TECH2h agoAfrica : COP17 - the World Has a Plan to Save Nature . Is It Working ? allafrica.com · NigeriaSCI & TECH2h agoHISTOINDEX AND A * STAR PARTNER TO ADVANCE EARLY - STAGE DEVELOPMENT OF PIPELINE THERAPIES FOR FIBROTIC DISEASESprnewswire.com · United States